SCYNEXIS, INC.
DURHAM, NC · CIK 0001178253 · Biotech · Public
Antifungal therapeutics for invasive fungal infections and rare fungal diseases
scynexis.com →- Grants
- $224K
- 1 award
- Sector median: 1
- Raised
- $5.5M
- 1 Form D · Dec 2011
- 178 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 5 granted · 35 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20112012201320142015
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,502,750 | |
| Federal grant | Department of Health and Human Services · Phase I · Non-Immunosuppressive Cyclosporine Analogs for Novel Antifungal Therapies | $223,992 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1169 | Tioga Pharmaceuticals Inc | — | $24M |
| 1170 | KODIAK BP, LLC | — | $13M |
| 1171 | Nova Mentis Life Science Corp. | — | $188K |
| 1172 | SCYNEXIS, INC. | — | $5.5M |
| 1173 | MediSix Therapeutics, Inc. | — | $35M |
| 1174 | ISOThrive Inc. | — | $17M |
| 1175 | Unleash Immuno Oncolytics, Inc. | — | $3.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Laurent ArthaudDirector
- Jose BarellaDirector
- Mounia ChaouiDirector
- Ann HanhamDirector
- Pamela KirbyDirector
- Patrick LangloisDirector
- Horace NalleDirector
- Jean-Yves NothiasDirector
- Charles Osborne, Jr.Executive Officer
- Ed PenhoetDirector
- Yves RibeillDirector · Executive Officer
- Brian SchwabExecutive Officer
Patents
- Triterpenoid Antifungals For The Treatment Or Prevention Of Pneumocystis Spp. Pneumoniagranted
- Antifungal Agents With Enhanced Activity In Acidic Phapplication
- Triterpenoid Antifungals For The Treatment Of Fungal Osteo-articular Infectionsapplication
- Injectable Compositions Of Triterpenoid Antifungals Encapsulated In Liposomesapplication
- Antifungal Agents With Enhanced Activity In Acidic Phapplication
- Injectable Compositions Of Triterpenoid Antifungals Encapsulated In Liposomesapplication
- Antifungal Agents With Enhanced Activity In Acidic Phgranted
- Antifungal Agents For Candida Auris Decolonizationapplication
- Antifungal Agents Used In Combinationapplication
- Triterpenoid Antifungals For The Treatment Of Fungal Osteo-articular Infectionsapplication
- Novel Salts And Polymorphs Of SCY-078application
- Antifungal Agents Used In Combinationgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.